Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC). Rosenberg, J. E., Sridhar, S. S., Zhang, J., Smith, D. C., Ruether, J. D., Flaig, T. W., Baranda, J., Lang, J., Plimack, E. R., Sangha, R. S., Heath, E. I., Merchan, J. R., Quinn, D. I., Srinivas, S., Milowsky, M. I., Wu, C., Gartner, E. M., Melhem-Bertrandt, A., Petrylak, D. AMER SOC CLINICAL ONCOLOGY. 2018

View details for DOI 10.1200/JCO.2018.36.15_suppl.4504

View details for Web of Science ID 000442916002031